Description: Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.
Home Page: www.allarity.com
ALLR Technical Analysis
210 Broadway
Cambridge,
MA
02139
United States
Phone:
401 426 4664
Officers
| Name | Title |
|---|---|
| Mr. James G. Cullem J.D. | Interim CEO, Chief Bus. Officer, Sr. VP of Corp. Devel. & Director |
| Dr. Marie Foegh DrSc, M.D. | Chief Medical Officer |
| Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D. | Co-Founder |
| Dr. Steen Meier Knudsen Ph.D. | Founder & Chief Scientific Officer |
| Mr. Thomas H. Jensen | Founder, Sr. VP of Investor Relations & Director |
| Mr. Claus Frisenberg Pedersen | Chief Commercial Officer |
| Ms. Joan Brown | Interim CFO & Director of Financial Reporting |
| Ms. Annie Rasmussen | Chief of Clinical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.659 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-12-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |